Respiratory Syncytial Virus trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Respiratory Syncytial Virus. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month8 studies across 4 companies, in the next 180 days.
August 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SNY | Sanofi | RSV Immunisation Status in Queensland (Australia)NCT07615192observationalThe proportion of immunised infants among all enrolled infants | — | Recruiting | 2026-08-20 | today | 2026-07-31 |
| PFE | Pfizer | A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.NCT07543380Percentage of participants reporting prompted local reactions within 7 days following investigational product administration | Phase 3 | Recruiting | 2026-08-31 | in 11 d | 2026-06-02 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | Impact and Effectiveness of ABRYSVO® Vaccination During PregnancyNCT06647654observationalRSV-associated LRTD hospitalization among infants | — | Active, not recruiting | 2026-10-01 | in 42 d | 2026-05-15 |
November 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National DatasetNCT07235397observationalPCR-confirmed RSV-associated LRTD hospitalization occurring ≤180 days after birth (first episode) | — | Not yet recruiting | 2026-11-13 | in 85 d | 2026-07-01 |
| PFE | Pfizer | Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic CosmosNCT07673081observationalIncidence of RSV-related Acute Respiratory Infection (ARI) hospitalization | — | Not yet recruiting | 2026-11-30 | in 102 d | 2026-06-29 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| 4507.T | Shionogi | A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe DiseaseNCT07214571Change From Baseline in RSV Ribonucleic Acid (RNA) Load by Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) (Nasopharyngeal Swab) at Day 2 | Phase 2 | Recruiting | 2026-12-30 | in 132 d | 2026-08-11 |
| ENTA | Enanta Pharmaceuticals, Inc | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial VirusNCT07482657Time to complete resolution of clinical signs of RSV as measured by RESOLVE-P | Phase 2 | Recruiting | Dec 2026 | ≤ 133 d | 2026-07-20 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreFNCT07653100Proportion of participants reporting local reactions within 7 days following investigational product administration | Phase 3 | Recruiting | 2027-01-25 | in 158 d | 2026-08-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Respiratory Syncytial Virus
most recently updated first106 studies match. Showing the first 100 of 106 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENTA | Enanta Pharmaceuticals, Inc | $387M | A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.NCT05568706results2026-08-19Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms | Phase 2 | Completed | Drug: EDP-938, Placebo | RSV Infection | 187 | 2022-11-29 | 2025-06-23actual | — | 2026-08-19 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy AdultsNCT07764237Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Phase 1 | Recruiting | Biological: mRNA-1365 (Profile 2), mRNA-1345 (Profile 1), mRNA-1345 (Profile 3) | Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (hMPV) | 375 | 2026-08-11 | 2027-07-20 | in 334 d | 2026-08-19 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial VirusNCT06097299results2026-08-18Part A (Cohorts 1 and 2): Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | Phase 2 | Completed | Biological: mRNA-1345, Placebo | Respiratory Syncytial Virus | 349 | 2023-10-24 | 2025-06-27actual | — | 2026-08-18 |
| PFE | Pfizer | $155.3B | A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised AdultsNCT07768345Percentage of participants reporting local reactions | Phase 3 | Not yet recruiting | Biological: RSVpreF Vaccine | Respiratory Syncytial Virus (RSV) | 440 | 2026-08-31 | 2028-02-02 | in 531 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single DoseNCT06866405Percentage of pregnant participants reporting local reactions | Phase 3 | Recruiting | Biological: RSVpreF, Placebo | RSV Infection | 550 | 2025-04-16 | 2028-02-24 | in 553 d | 2026-08-14 |
| PFE | Pfizer | $155.3B | A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreFNCT07653100Proportion of participants reporting local reactions within 7 days following investigational product administration | Phase 3 | Recruiting | Biological: RSVpreF, Placebo | Respiratory Syncytial Virus (RSV) | 540 | 2026-06-22 | 2027-01-25 | in 158 d | 2026-08-14 |
| 4507.T | Shionogi | $15.7B | A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe DiseaseNCT07214571Change From Baseline in RSV Ribonucleic Acid (RNA) Load by Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) (Nasopharyngeal Swab) at Day 2 | Phase 2 | Recruiting | Drug: S-337395, Placebo | Respiratory Syncytial Virus Infections | 192 | 2025-12-11 | 2026-12-30 | in 132 d | 2026-08-11 |
| SNY | Sanofi | — | An Observational Study to Assess Nirsevimab Immunization Rates in Eligible Infants During Their First RSV Season in the CzechiaNCT07634692observationalThe proportion of immunised infants among all enrolled infants | — | Completed | Biological: Nirsevimab Respiratory Syncytial Virus monoclonal antibody | RSV Immunization | 257 | 2026-06-15 | 2026-06-26actual | — | 2026-08-10 |
| SNY | Sanofi | — | RSV Immunisation Status in Queensland (Australia)NCT07615192observationalThe proportion of immunised infants among all enrolled infants | — | Recruiting | Biological: Nirsevimab Respiratory Syncytial Virus monoclonal antibody | RSV Immunization | 1,200 | 2026-05-29 | 2026-08-20 | today | 2026-07-31 |
| SNY | Sanofi | — | Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and OlderNCT07734649RSV A serum nAb (neutralizing antibodies) titers | Phase 1/2 | Recruiting | Biological: RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Control Vaccine 1 · Other: Placebo | Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers | 2,400 | 2026-07-22 | 2028-05-03 | in 622 d | 2026-07-29 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial VirusNCT07482657Time to complete resolution of clinical signs of RSV as measured by RESOLVE-P | Phase 2 | Recruiting | Drug: zelicapavir, Placebo | RSV Infection, RSV, Respiratory Syncytial Virus (RSV) | 150 | 2026-07-09 | Dec 2026 | ≤ 133 d | 2026-07-20 |
| AZN | AstraZeneca | — | Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) DiseaseNCT06851806To assess the safety of palivizumab prophylaxis when administered to preterm infants (≤ 35 wGA), children with BPD (< 24 months) and/or children with haemodynamically significant CHD (< 24 months). | Not applicable | Recruiting | Drug: Palivizumab 15 mg/kg | Respiratory Syncytial Virus (RSV) | 138 | 2025-12-10 | 2027-02-28 | in 192 d | 2026-07-09 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their InfantsNCT06325657results2026-07-02Percentage of Maternal Participants With Prespecified Local Reactions Within 7 Days After Vaccination | Phase 3 | Completed | Biological: RSVpreF vaccine, Placebp | Respiratory Syncytial Virus | 681 | 2024-03-12 | 2025-06-11actual | — | 2026-07-02 |
| PFE | Pfizer | $155.3B | Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National DatasetNCT07235397observationalPCR-confirmed RSV-associated LRTD hospitalization occurring ≤180 days after birth (first episode) | — | Not yet recruiting | Biological: ABRYSVO | Respiratory Syncytial Virus Infections | 1 | 2026-07-30 | 2026-11-13 | in 85 d | 2026-07-01 |
| GILD | Gilead Sciences | $177.9B | Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) InfectionNCT06585150results2026-06-30Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Through Day 15 | Phase 2 | Terminatedsponsor's stated reason: Study was terminated by Sponsor; the decision was not due to any safety findings. | Drug: Obeldesivir, Obeldesivir Placebo | RSV Infection | 150 | 2024-10-14 | 2025-05-08actual | — | 2026-06-30 |
| PFE | Pfizer | $155.3B | Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic CosmosNCT07673081observationalIncidence of RSV-related Acute Respiratory Infection (ARI) hospitalization | — | Not yet recruiting | — | Respiratory Syncytial Virus (RSV) | 293,334 | 2026-06-20 | 2026-11-30 | in 102 d | 2026-06-29 |
| MRNA | ModernaTX, Inc. | $25.1B | A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 MonthsNCT05743881Main Study: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Phase 1 | Active, not recruiting | Biological: mRNA-1345, mRNA-1365, Placebo · Drug: Nimenrix | Respiratory Syncytial Virus, Human Metapneumovirus | 186 | 2023-02-15 | 2029-08-31 | in 1,107 d | 2026-06-26 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersNCT06143046Number of Maternal Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Phase 2 | Completed | Biological: mRNA-1345, Placebo | Respiratory Syncytial Virus | 360 | 2023-11-15 | 2026-05-25actual | — | 2026-06-10 |
| PFE | Pfizer | $155.3B | Evaluating ABRYSVO Maternal Vaccine Effectiveness Among InfantsNCT07249320observationalPolymerase chain reaction (PCR)-confirmed RSV LRTD occurring ≤180 days after birth (first episode). | — | Active, not recruiting | Biological: ABRYSVO | Respiratory Syncytial Virus (RSV) | 1 | 2025-12-01 | 2027-09-30 | in 406 d | 2026-06-10 |
| GILD | Gilead Sciences | $177.9B | Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) InfectionNCT06784973results2026-06-08Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) by Day 28 | Phase 2 | Terminatedsponsor's stated reason: Study was terminated by Sponsor; the decision was not due to any safety findings. | Drug: Obeldesivir, Obeldesivir Placebo | RSV Infection | 4 | 2025-03-05 | 2025-04-16actual | — | 2026-06-08 |
| PFE | Pfizer | $155.3B | A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.NCT07543380Percentage of participants reporting prompted local reactions within 7 days following investigational product administration | Phase 3 | Recruiting | Biological: RSVpreF | Respiratory Syncytial Virus (RSV) | 130 | 2026-05-11 | 2026-08-31 | in 11 d | 2026-06-02 |
| PFE | Pfizer | $155.3B | Impact and Effectiveness of ABRYSVO® Vaccination During PregnancyNCT06647654observationalRSV-associated LRTD hospitalization among infants | — | Active, not recruiting | Biological: ABRYSVO | Respiratory Syncytial Virus, Respiratory Tract Diseases | 1 | 2024-08-26 | 2026-10-01 | in 42 d | 2026-05-15 |
| PFE | Pfizer | $155.3B | A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) DiseaseNCT06077968observational1. Vaccine Effectiveness (VE) calculated as 1 minus the odds ratio (OR) comparing the odds of being vaccinated with ABRYSVO for RSV-related hospitalized LRTD cases and controls, multiplied by 100%. | — | Active, not recruiting | Biological: Prior standard of care receipt of Pfizer's ABRYSVO vaccine | Respiratory Syncytial Viruses | 1 | 2023-11-01 | 2029-05-01 | in 985 d | 2026-05-11 |
| SNY | Sanofi | — | Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of AgeNCT07516418Presence of any unsolicited systemic Adverse Events (AEs) reported within 30 minutes after vaccination | Phase 1 | Recruiting | Biological: H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3, RSV IMP 4, RSV IMP 5, RSV IMP 6, H5 Flu IMP 7, H5 Flu IMP 8, H5 Flu IMP 9, H5 Flu IMP 10, H5 Flu IMP 11, H5 Flu IMP 12 | Respiratory Syncytial Virus (RSV), Influenza A(H5N1) | 570 | 2026-04-15 | 2027-04-04 | in 227 d | 2026-05-08 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of AgeNCT07117487Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Phase 3 | Completed | Biological: mRNA-1345 | Respiratory Syncytial Virus | 507 | 2025-08-05 | 2026-03-27actual | — | 2026-05-04 |
| SNY | Sanofi | — | Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of AgeNCT07071558Presence of any unsolicited systemic adverse events (aes) | Phase 1 | Completed | Biological: RSV vaccine formulation 1 dose, RSV vaccine formulation 2 dose, RSV vaccine formulation 3 dose, RSV vaccine formulation 4 dose, RSV vaccine formulation 5 dose, RSV vaccine formulation 6 dose, RSV vaccine formulation 7 dose, RSV vaccine formulation 8 dose | Respiratory Syncytial Virus Immunization | 240 | 2025-07-14 | 2026-03-17actual | — | 2026-04-28 |
| AZN | AstraZeneca | — | A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of NirsevimabNCT06042049results2026-04-16Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs), and New-onset Chronic Diseases (NOCDs) | Phase 3 | Completed | Drug: Nirsevimab | Respiratory Syncytial Virus Infections | 33 | 2023-07-27 | 2025-07-24actual | — | 2026-04-16 |
| SNY | Sanofi | — | Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in IndiaNCT07109297Presence of immediate adverse events (AEs) | Phase 4 | Active, not recruiting | Biological: Nirsevimab | RSV Immunization | 110 | 2025-07-31 | 2026-06-30 | — | 2026-03-23 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of Modified mRNA Vaccines in Healthy AdultsNCT05397223Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) | Phase 1 | Completed | Biological: mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647 | SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus | 308 | 2022-05-24 | 2026-02-27actual | — | 2026-03-12 |
| PFE | Pfizer | $155.3B | A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in KoreaNCT06593587results2026-02-09Percentage of Participants With Local Reactions Within 7 Days After Vaccination | Phase 3 | Completed | Biological: RSVpreF Vaccine · Other: Placebo | Respiratory Syncytial Virus | 378 | 2024-10-07 | 2025-02-03actual | — | 2026-02-09 |
| PFE | Pfizer | $155.3B | SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDERNCT06546800observationalPercentage of individuals aged 60 years or older reporting Adverse Reactions for 28 days after vaccination. | — | Active, not recruiting | Biological: RSVpreF vaccine | Respiratory Syncytial Virus Infection | 1,100 | 2025-05-27 | 2027-10-28 | in 434 d | 2026-02-04 |
| PFE | Pfizer | $155.3B | Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western PennsylvaniaNCT06813872observationalRSV-positive ARI hospitalization confirmed by ³1 ARI symptom, laboratory testing, and hospitalization occurring 0 to ≤ 90 days of life during RSV season based on local epidemiology. | — | Active, not recruiting | Biological: ABRYSVO Vaccination | Respiratory Syncytial Viruses | 1 | 2025-02-24 | 2027-07-31 | in 345 d | 2026-02-03 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of AgeNCT05330975results2025-12-30Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection | Phase 3 | Completed | Biological: Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214 | Respiratory Syncytial Virus | 3,317 | 2022-04-01 | 2024-11-08actual | — | 2025-12-30 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSVNCT06102174results2025-12-30Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 1 | Terminatedsponsor's stated reason: Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study | Drug: Placebo, Active | Respiratory Syncytial Virus Infections | 10 | 2024-02-15 | 2024-09-03actual | — | 2025-12-30 |
| SNY | Sanofi | — | A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of KoreaNCT07200206observationalOccurence of Adverse Events (AEs) | — | Recruiting | Biological: Nirsevimab | Respiratory Syncytial Virus | 3,000 | 2025-10-02 | 2029-09-26 | in 1,133 d | 2025-12-03 |
| PFE | Pfizer | $155.3B | STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)NCT07122661observationalEstimate vaccine effectiveness of ABRYSVO during pregnancy against RSV-positive lower respiratory tract disease hospitalisation among infants. | — | Active, not recruiting | Biological: ABRYSVO | Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus, Lower Respiratory Tract Disease, Respiratory Tract Diseases, Acute Respiratory Illness (ARI) | 1 | 2025-08-11 | 2027-04-30 | in 253 d | 2025-11-19 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) InfectionNCT06079320results2025-11-10Number of Participants With Respiratory Syncytial Virus (RSV) Related Hospitalization or Death From Any Cause Through Day 28 | Phase 2/3 | Terminatedsponsor's stated reason: Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study. | Drug: Sisunatovir, Placebo | Respiratory Syncytial Virus Infection | 16 | 2023-12-08 | 2024-09-30actual | — | 2025-11-10 |
| PFE | Pfizer | $155.3B | A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in AdultsNCT06890416Geometric Mean Ratio (GMR) of Neutralizing Titer (NTs) for RSV A and B in RSVpreF + herpes zoster subunit vaccine (HZ/su) Compared to RSVpreF Alone | Phase 3 | Completed | Biological: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, HZ/su VACCINE | Respiratory Syncytial Virus (RSV) | 526 | 2025-04-04 | 2025-09-30actual | — | 2025-11-06 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge ModelNCT06170242results2025-10-07Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC) | Phase 2 | Completed | Drug: EDP-323 Dose Regimen 1, EDP-323 Dose Regimen 2, Placebo | RSV Infection | 142 | 2023-11-20 | 2024-06-17actual | — | 2025-10-07 |
| PFE | Pfizer | $155.3B | A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.NCT06473519results2025-09-25Geometric Mean Titer (GMT) of Serum Neutralizing Titers (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) and Respiratory Syncytial Virus Subgroup B (RSV B) Before Vaccination | Phase 3 | Completed | Biological: RSVpreF MDV, RSVpreF SDV | Respiratory Syncytial Virus (RSV) | 453 | 2024-06-24 | 2024-09-20actual | — | 2025-09-25 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of AgeNCT05127434Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Phase 2/3 | Completed | Drug: Placebo, mRNA-1345 | Respiratory Syncytial Virus | 36,814 | 2021-11-17 | 2025-07-28actual | — | 2025-08-19 |
| PFE | Pfizer | $155.3B | A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV DiseaseNCT05842967results2025-08-08SSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination | Phase 3 | Completed | Biological: RSVpreF · Other: Placebo | RESPIRATORY SYNCYTIAL VIRUS (RSV) | 885 | 2023-05-11 | 2024-03-18actual | — | 2025-08-08 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsNCT06067230Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Phase 3 | Active, not recruiting | Biological: mRNA-1345 | Respiratory Syncytial Virus | 1,153 | 2023-10-06 | 2026-07-30 | — | 2025-08-08 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) InfectionNCT03258502Change in viral load | Phase 2 | Completed | Drug: RV521, Placebo | Respiratory Syncytial Virus Infections | 66 | 2017-07-19 | 2017-10-31actual | — | 2025-07-31 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of AgeNCT06060457results2025-07-30Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection | Phase 3 | Completed | Biological: Placebo, mRNA-1345, Fluzone HD | Respiratory Syncytial Virus | 1,900 | 2023-09-25 | 2024-06-07actual | — | 2025-07-30 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | A Study to Evaluate EDP 938 Regimens in Children With RSVNCT04816721results2025-07-08Part 1: Concentrations of EDP-938 in Plasma | Phase 2 | Completed | Drug: EDP-938, Placebo | Respiratory Syncytial Virus (RSV) | 99 | 2022-04-26 | 2024-08-19actual | — | 2025-07-28 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy AdultsNCT06601192Time-matched, placebo-corrected change-from-baseline QTc based on the Fridericia correction QTcF (ΔΔQTcF) after TD and SD of Zelicapavir | Phase 1 | Completed | Drug: zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), Placebo, moxifloxacin | RSV Infection, QTc Interval | 72 | 2024-07-15 | 2025-02-02actual | — | 2025-07-28 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.NCT06847464Cmax of EDP-323 with and without coadministration with Itraconazole | Phase 1 | Completed | Drug: EDP-323, Itraconazole, EDP-323, carbamazepine, EDP-323, Quinidine, EDP-323, fluconazole | RSV Infection, Drug Drug Interaction (DDI) | 48 | 2025-01-27 | 2025-05-24actual | — | 2025-07-01 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy ParticipantsNCT06917508Cmax of midazolam, caffeine, and rosuvastatin with and without the coadministration of EDP-323 | Phase 1 | Completed | Drug: EDP-323, Midazolam, Caffeine, Rosuvastatin | RSV Infection, Drug Drug Interaction | 24 | 2025-03-13 | 2025-06-06actual | — | 2025-07-01 |
| NVAX | Novavax | $1.3B | A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal ImmunizationNCT02624947results2025-05-06Infants: Percentages of Participants With Medically Significant RSV LRTI With Either Hypoxemia (SpO2 <95% at Sea Level or <92% at Altitudes >1800 Meters) or Tachypnea | Phase 3 | Completed | Biological: RSV F vaccine with adjuvant, Formulation buffer | Respiratory Syncytial Virus Infections | 4,636 | Dec 2015 | 2018-12-28actual | — | 2025-05-06 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of AgeNCT05900154results2025-03-06Percentage of Participants With Local Reactions Within 7 Days After Vaccination | Phase 1 | Completed | Biological: RSVpreF 120 µg, RSVpreF 60 µg | RESPIRATORY SYNCYTIAL VIRUS (RSV) | 128 | 2023-06-22 | 2024-02-29actual | — | 2025-03-06 |
| PFE | Pfizer | $155.3B | A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.NCT05987072results2025-02-24Maximum Observed Plasma Concentration (Cmax) of Sisunatovir on Day 1 | Phase 1 | Completed | Drug: Sisunatovir | Respiratory Syncytial Virus Infection | 12 | 2023-11-03 | 2023-12-31actual | — | 2025-02-24 |
| MRNA | ModernaTX, Inc. | $25.1B | Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) StudyNCT05572658observationalRate of Hospitalizations for Cardiopulmonary, Cardiovascular, Respiratory, Pneumonia/Influenza, Pneumonia and Complications, or RSV | — | Completed | Biological: mRNA-1345, Placebo | Respiratory Syncytial Virus | 10,994 | 2022-09-15 | 2023-09-30actual | — | 2025-01-24 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.NCT04225897results2024-10-23Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Permanent Discontinuation of IMP | Phase 2 | Terminatedsponsor's stated reason: Part A and Part B were completed but Pfizer terminated Part C due to strategic consideration. There were no safety concerns in the decision to stop Part C and no changes to the risk-benefit for participants who received RV521 in the study. | Drug: RV521, Placebo | Respiratory Syncytial Virus (RSV), Lower Resp Tract Infection | 51 | 2019-11-13 | 2022-12-05actual | — | 2024-10-23 |
| PFE | Pfizer | $155.3B | Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)NCT06067191results2024-10-21Area Under the Curve (AUC) for RSV-A Memphis 37b Viral Load Determined by Quantitative Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) | Phase 1 | Completed | Drug: RV299, Placebo | Respiratory Syncytial Virus (RSV) | 82 | 2022-08-08 | 2022-12-02actual | — | 2024-10-21 |
| PFE | Pfizer | $155.3B | A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult ParticipantsNCT05712460results2024-09-19Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 1 | Completed | Drug: sisunatovir, Placebo | Respiratory Syncytial Viruses | 12 | 2023-02-08 | 2023-04-28actual | — | 2024-09-19 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory TractNCT04633187results2024-08-22Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication | Phase 2 | Terminatedsponsor's stated reason: Study was terminated due to a strategic business decision and not due to safety concerns. | Drug: EDP-938, Placebo | Respiratory Syncytial Virus Infections | 9 | 2021-07-07 | 2023-05-31actual | — | 2024-08-22 |
| MRNA | ModernaTX, Inc. | $25.1B | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-SeropositiveNCT04528719Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Phase 1 | Completed | Biological: mRNA-1345 · Drug: Placebo | Respiratory Syncytial Virus | 651 | 2020-09-30 | 2024-07-18actual | — | 2024-08-07 |
| PFE | Pfizer | $155.3B | Pharmacokinetics and Safety of RV521 FormulationsNCT04065698Time to maximum plasma concentration (tmax) for RV521 | Phase 1 | Completed | Drug: RV521 | Respiratory Syncytial Virus Infections | 9 | 2019-08-13 | 2019-09-02actual | — | 2024-06-07 |
| PFE | Pfizer | $155.3B | A Study to Learn About Effect of Sisunatovir in Healthy Adult Male ParticipantsNCT05873764Tmax (Time of maximum observed concentration) | Phase 1 | Completed | Drug: 200 mg RV521/78 µCi [ 14C]-RV521. | Respiratory Syncytial Virus Infections | 9 | 2022-05-25 | 2022-07-12actual | — | 2024-05-16 |
| TMO | Thermo Fisher Scientific, Inc | $217.8B | Project STARFISH - PRJ0002679NCT05727202observationalPrimary Endpoint | — | Completed | Diagnostic test: The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel | SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection | 1,909 | 2023-02-20 | 2024-04-02actual | — | 2024-04-30 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult ParticipantsNCT03782662Effect of RV521 on Cmax of Midazolam | Phase 1 | Completed | Drug: Itraconazole, Verapamil, Rifampicin, Midazolam, Placebo for RV521, RV521 | Respiratory Syncytial Virus Infections | 82 | 2018-11-07 | 2019-03-17actual | — | 2024-04-22 |
| MRNA | ModernaTX, Inc. | $25.1B | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years OldNCT05585632Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Phase 1 | Completed | Biological: mRNA-1010, mRNA-1345, mRNA-1273.214, mRNA-1045, mRNA-1230 | SARS-CoV-2, Influenza, RSV | 392 | 2022-10-14 | 2024-02-28actual | — | 2024-03-08 |
| 4568.T | Daiichi Sankyo | $31.7B | A Dose Finding Study of VN-0200NCT05547087Geometric Mean Titer (GMT) of anti-RSV Subgroup A (RSV/A) Neutralizing Activity | Phase 2 | Completed | Biological: VN-0200 | Respiratory Syncytial Virus Infections | 342 | 2022-10-13 | 2023-04-11actual | — | 2024-02-29 |
| AZN | AstraZeneca | — | A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)NCT03979313results2024-02-28Number of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort) | Phase 3 | Completed | Drug: MEDI8897, Placebo | Respiratory Syncytial Virus Infections | 3,012 | 2019-07-23 | 2021-03-11actual | — | 2024-02-28 |
| AZN | AstraZeneca | — | Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised ChildrenNCT04484935results2023-11-15Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs (TESAEs), AEs of Special Interest (AESIs), and New Onset Chronic Disease (NOCDs) | Phase 2 | Completed | Drug: Nirsevimab | RSV Infection | 100 | 2020-08-19 | 2023-02-17actual | — | 2023-11-15 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult SubjectsNCT04196101results2023-10-30Total Symptom Score (TSS) Area Under the Curve (AUC) | Phase 2 | Completed | Drug: EDP-938, Placebo | Respiratory Syncytial Virus | 82 | 2020-01-22 | 2022-01-04actual | — | 2023-10-30 |
| PFE | Pfizer | $155.3B | Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of AgeNCT05301322results2023-10-27Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination With RSVpreF or Placebo | Phase 3 | Completed | Biological: RSVpreF Vaccine, Seasonal Inactivated Influenza Vaccine · Other: Placebo | Respiratory Syncytial Virus | 1,471 | 2022-04-13 | 2022-10-12actual | — | 2023-10-27 |
| AZN | AstraZeneca | — | A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk ChildrenNCT03959488results2023-09-21Safety and Tolerability of MEDI8897 as Assessed by the Occurrence of All Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs) and New Onset Chronic Disease (NOCD) | Phase 2/3 | Completed | Drug: MEDI8897, Palivizumab | Respiratory Syncytial Virus Infections | 925 | 2019-07-30 | 2021-05-03actual | — | 2023-09-21 |
| PFE | Pfizer | $155.3B | Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy AdultsNCT06033612Number of participants with treatment-emergent adverse events (TEAE) as assessed by CTCAE V5.0. | Phase 1 | Completed | Drug: RV299, Placebo, Midazolam | Respiratory Syncytial Virus Infections | 50 | 2021-11-12 | 2022-07-27actual | — | 2023-09-13 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | A Study of EDP-323 in Healthy SubjectsNCT05587478Safety measured by adverse events | Phase 1 | Completed | Drug: EDP-323, Placebo | RSV Infection | 82 | 2022-09-29 | 2023-03-29actual | — | 2023-09-01 |
| PFE | Pfizer | $155.3B | Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSVNCT04267822Proportion of subjects with a progression to Lower Respiratory Tract Complication (LRTC) during the study | Phase 2 | Withdrawnsponsor's stated reason: No recruitment | Drug: RV521 oral tablet, Placebo oral tablet | RSV Infection, Stem Cell Transplant Complications, Lower Resp Tract Infection | 0 | 2020-06-15 | 2023-06-30 | — | 2023-05-08 |
| PFE | Pfizer | $155.3B | Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of AgeNCT05096208results2023-04-12Geometric Mean Ratios (GMRs) of Respiratory Syncytial Virus Subgroup A (RSV A) and B (RSV B) Neutralizing Antibodies at 1 Month After Vaccination for Every Pair of RSVpreF Lots | Phase 3 | Completed | Biological: RSVpreF (Group 1), RSVpreF (Group 2), RSVpreF (Group 3), Placebo | RSV | 1,028 | 2021-10-21 | 2022-04-04actual | — | 2023-04-12 |
| NVAX | Novavax | $1.3B | A Study to Evaluate the Efficacy of an RSV F Vaccine in Older AdultsNCT02608502Numbers and percentages of subjects with moderate-severe RSV-LRTD | Phase 3 | Completed | Biological: RSV-F Vaccine, Phosphate Buffer Placebo | Respiratory Syncytial Virus (RSV) | 11,850 | Nov 2015 | Dec 2016actual | — | 2022-07-19 |
| NVAX | Novavax | $1.3B | RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.NCT02247726Counts and percentage of subjects with solicited injection site and systemic reactogenicity within seven days of vaccination. | Phase 2 | Completed | Drug: Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL injection) | Respiratory Syncytial Virus Infections | 50 | Sep 2014 | Jul 2016actual | — | 2022-05-27 |
| NVAX | Novavax | $1.3B | Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly AdultsNCT02266628Immunogenicity as assessed by serum IgG antibody titers specific for the F-Protein antigen | Phase 2 | Completed | Biological: RSV-F Vaccine, Saline Placebo | Respiratory Syncytial Virus (RSV) | 1,599 | Oct 2014 | Mar 2016actual | — | 2022-05-27 |
| NVAX | Novavax | $1.3B | Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.NCT02593071Serum IgG antibody concentrations as ELISA units (EUs) specific for the F protein antigen. | Phase 2 | Completed | Biological: RSV-F Vaccine, Phosphate Buffer Placebo | Respiratory Syncytial Virus (RSV) | 1,330 | Oct 2015 | Nov 2016actual | — | 2022-05-27 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge ModelNCT03691623results2022-05-03Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral Load | Phase 2 | Completed | Drug: EDP-938 Dose 1, EDP-938 Dose 2, Placebo, EDP-938 Dose 3, EDP-938 Dose 4, Placebo | RSV Infection | 179 | 2018-10-15 | 2019-09-30actual | — | 2022-05-03 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male SubjectsNCT04927793Cmax of EDP-938 in plasma | Phase 1 | Completed | Drug: EDP-938 | Respiratory Syncytial Virus (RSV) | 8 | 2021-05-28 | 2021-07-04actual | — | 2022-03-23 |
| 4568.T | Daiichi Sankyo Co., Ltd. | $31.7B | Study of VN-0200 in Japanese Healthy Adults and Elderly SubjectsNCT04914520Number of Participants Reporting Treatment-emergent Adverse Events | Phase 1 | Completed | Biological: VN-0200, Placebo | Respiratory Syncytial Virus Infections | 48 | 2021-06-11 | 2021-12-16actual | — | 2021-12-22 |
| NVAX | Novavax | $1.3B | Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older AdultsNCT03026348Neutralizing antibody titers to at least one RSV/A strain | Phase 2 | Completed | Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant, RSV F Vaccine, Matrix-M1 Adjuvant · Other: Phosphate Buffer | Respiratory Syncytial Viruses | 300 | Jan 2017 | Apr 2017actual | — | 2021-12-06 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy SubjectsNCT04498741Cmax of tacrolimus with and without coadministration with EDP-938 | Phase 1 | Completed | Drug: EDP-938, EDP-938, EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, EDP-938, Midazolam | RSV Infection | 89 | 2020-07-08 | 2021-05-27actual | — | 2021-10-13 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy SubjectsNCT04871724Cmax of EDP-938 with and without coadministration with fluconazole | Phase 1 | Completed | Drug: EDP-938, Fluconazole | RSV Infection | 24 | 2021-03-12 | 2021-03-30actual | — | 2021-05-04 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy SubjectsNCT03755778Cmax of EDP-938 with and without coadministration with itraconazole | Phase 1 | Completed | Drug: EDP-938, EDP-938, EDP-938, Itraconazole, Rifampin, Quinidine | RSV Infection | 72 | 2018-11-29 | 2019-01-21actual | — | 2019-06-14 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult SubjectsNCT03750383Cmax of EDP-938 with and without coadministration with cyclosporine | Phase 1 | Completed | Drug: EDP-938, EDP-938, Cyclosporine, Prednisone | RSV Infection | 48 | 2018-11-02 | 2018-11-17actual | — | 2019-02-12 |
| GILD | Gilead Sciences | $177.9B | Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) InfectionNCT02534350results2018-11-28Time-Weighted Average Change in Viral Load From Day 1/Baseline Through Day 7 in Participants in the Full Analysis Set | Phase 2 | Completed | Drug: Presatovir, Placebo | Respiratory Syncytial Virus (RSV) | 61 | 2015-12-31 | 2017-02-20actual | — | 2018-11-28 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm InfantsNCT02325791results2018-11-06Part A: Serum Concentration of Suptavumab Over Time | Phase 3 | Completed | Drug: Suptavumab 30 mg/kg, Placebo Matched to Suptavumab, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses | Respiratory Syncytial Virus Infections | 1,177 | 2015-07-21 | 2017-07-05actual | — | 2018-11-06 |
| ENTA | Enanta Pharmaceuticals, Inc | $387M | A Study of EDP-938 in Healthy SubjectsNCT03384823Safety measured by adverse events, physical exams, vital signs, 12-lead electrocardiograms (ECGs) and clinical lab results (including chemistry, hematology, and urinalysis). | Phase 1 | Completed | Drug: EDP-938, Placebo | RSV Infection | 90 | 2017-12-07 | 2018-07-03actual | — | 2018-10-10 |
| GILD | Gilead Sciences | $177.9B | Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) InfectionNCT02135614results2018-05-11Time-Weighted Average Change in Respiratory Syncytial Viral (RSV) Load From Baseline to Day 5 | Phase 2 | Completed | Drug: Presatovir, Presatovir placebo | Respiratory Syncytial Virus Infection | 189 | 2014-06-09 | 2017-03-27actual | — | 2018-09-24 |
| GILD | Gilead Sciences | $177.9B | Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory TractNCT02254421results2018-05-11Time-weighted Average Change in Nasal Respiratory Syncytial Viral (RSV) Load From Baseline to Day 9 | Phase 2 | Completed | Drug: Presatovir, Placebo | Respiratory Syncytial Virus Infection | 60 | 2015-01-31 | 2017-04-17actual | — | 2018-09-24 |
| VXRT | Vaxart | $124M | Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)NCT02830932Systemic Reactogenicity of VXA-RSV-f vaccine delivered by oral enteric tablet. | Phase 1 | Completed | Biological: VXA-RSV-f Tablets (high dose), VXA-RSV-f Tablets (low dose) · Other: VXA Placebo Tablets | Respiratory Syncytial Virus (RSV) | 66 | 2016-06-22 | 2016-09-16actual | — | 2018-08-16 |
| GILD | Gilead Sciences | $177.9B | Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory TractNCT02254408results2018-08-06Time-Weighted Average Change in Nasal Respiratory Syncytial Virus (RSV ) Viral Load From Baseline (Day 1) to Day 9 | Phase 2 | Completed | Drug: Presatovir, Placebo | Respiratory Syncytial Virus | 189 | 2015-01-23 | 2017-07-14actual | — | 2018-08-06 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of BelarusNCT02968173results2018-03-13Percentage of Participants With RSV Hospitalization | Phase 3 | Completed | Drug: Palivizumab | Respiratory Syncytial Virus (RSV) | 50 | 2016-11-09 | 2017-07-13actual | — | 2018-03-13 |
| ALNY | Alnylam Pharmaceuticals | $30.6B | Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)NCT01065935The occurrence of new or progressive BOS grade 0p through 3 in RSV-infected lung transplant recipients | Phase 2 | Completed | Drug: ALN-RSV01, Normal Saline | Respiratory Syncytial Virus Infections | 87 | Feb 2010 | Apr 2012actual | — | 2018-02-05 |
| ALNY | Alnylam Pharmaceuticals | $30.6B | Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)NCT00658086Assess safety and tolerability of aerosolized ALN-RSV01 versus placebo in lung transplant patients infected with RSV | Phase 2 | Completed | Drug: ALN-RSV01, normal saline | Respiratory Syncytial Virus Infections | 24 | Apr 2008 | Apr 2009actual | — | 2018-01-29 |
| ABBV | AbbVie | $457.5B | Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®NCT02016690results2017-02-08observationalNumber of Participants With Adverse Events | — | Completed | — | Respiratory Syncytial Virus Infection | 312 | Dec 2013 | Dec 2015actual | — | 2017-03-20 |
| ABBV | AbbVie | $457.5B | Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab ImmunoprophylaxisNCT02282982results2016-06-28observationalProportion of Infants Hospitalized for Lower Respiratory Tract Infection (LRTI) With a Positive Respiratory Syncytial Virus (RSV) Diagnostic Test | — | Completed | — | Respiratory Syncytial Virus (RSV) | 359 | Oct 2014 | May 2015actual | — | 2016-07-29 |
| NVAX | Novavax | $1.3B | RSV F Dose-Ranging Study in WomenNCT01960686Immunogenicity as assessed by serum IgG antibody titers specific for the F-Protein antigen across treatment groups | Phase 2 | Completed | Biological: Low dose RSV F Antigen, High dose RSV F Antigen, Dose 1 of Aluminum Adjuvant, Dose 2 of Aluminum Adjuvant, Dose 3 of Aluminum Adjuvant, Dose 4 of Aluminum Adjuvant, Placebo | Respiratory Syncytial Virus Infections | 720 | Oct 2013 | Apr 2014actual | — | 2016-05-26 |
| GILD | Gilead Sciences | $177.9B | Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)NCT01756482Change in viral load measurements. | Phase 2 | Completed | Drug: GS-5806, Placebo | Respiratory Syncytial Virus Infections | 140 | Nov 2012 | Jun 2013actual | — | 2015-08-21 |
| NVAX | Novavax | $1.3B | RSV-F Vaccine Dose Ranging Study in Young WomenNCT01704365Immunogenicity as assessed by serum IgG antibody titers specific for the F-Protein antigen across treatment groups | Phase 2 | Completed | Biological: Low dose RSV-F Vaccine with Adjuvant, Low dose RSV-F Vaccine without Adjuvant, High dose RSV-F Vaccine with Adjuvant, High dose RSV-F Vaccine without Adjuvant, Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing], Placebo | Respiratory Syncytial Virus (RSV) | 330 | Oct 2012 | Apr 2013actual | — | 2014-03-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Respiratory Syncytial Virus is matched — 9 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Respiratory Syncytial Virus (RSV)
- Respiratory Syncytial Virus Infections
- RSV Infection
- Respiratory Syncytial Virus
- Respiratory Syncytial Virus Infection
- Respiratory Syncytial Viruses
- RSV
- RSV Immunization
- Respiratory Syncytial Virus Immunization
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Respiratory Syncytial Virus” (a text search, wider than this page)